Jefferies Group LLC reaffirmed their buy rating on shares of Celgene Corporation (NASDAQ:CELG) in a report released on Tuesday morning, MarketBeat Ratings reports. The firm currently has a $160.00 price objective on the biopharmaceutical company’s stock.

CELG has been the topic of a number of other research reports. Cantor Fitzgerald set a $159.00 target price on Celgene Corporation and gave the company a buy rating in a report on Thursday, April 27th. Leerink Swann reissued a market perform rating on shares of Celgene Corporation in a report on Monday, March 20th. Cann reissued a buy rating and issued a $148.00 target price on shares of Celgene Corporation in a report on Tuesday, April 4th. Canaccord Genuity set a $156.00 target price on Celgene Corporation and gave the company a buy rating in a report on Tuesday, June 6th. Finally, BidaskClub raised Celgene Corporation from a sell rating to a hold rating in a report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have given a buy rating to the stock. Celgene Corporation currently has an average rating of Buy and a consensus target price of $141.00.

Shares of Celgene Corporation (CELG) opened at 134.57 on Tuesday. The stock has a market cap of $105.08 billion, a price-to-earnings ratio of 50.53 and a beta of 1.89. The firm has a 50-day moving average price of $121.46 and a 200 day moving average price of $120.59. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $135.99.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.21. The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3.04 billion. Celgene Corporation had a return on equity of 70.94% and a net margin of 18.32%. The company’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.32 earnings per share. Analysts expect that Celgene Corporation will post $7.28 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/jefferies-group-llc-reaffirms-buy-rating-for-celgene-corporation-nasdaqcelg/1444714.html.

In related news, insider Robert J. Hugin sold 175,970 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now directly owns 1,033,909 shares in the company, valued at $138,688,553.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James J. Loughlin sold 9,250 shares of the stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $124.00, for a total value of $1,147,000.00. Following the transaction, the director now owns 32,169 shares in the company, valued at $3,988,956. The disclosure for this sale can be found here. Insiders have sold 237,005 shares of company stock worth $31,515,142 over the last quarter. 0.95% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in CELG. Diversified Trust Co raised its stake in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares in the last quarter. Sowell Financial Services LLC raised its stake in shares of Celgene Corporation by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 13 shares in the last quarter. South Texas Money Management Ltd. raised its stake in shares of Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares in the last quarter. Flagship Harbor Advisors LLC raised its stake in shares of Celgene Corporation by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares in the last quarter. Finally, Keel Point LLC raised its stake in shares of Celgene Corporation by 0.9% in the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 28 shares in the last quarter. Institutional investors own 78.16% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.